NASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis $19.63 -0.12 (-0.61%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARWR alerts:Sign Up Key Stats Today's Range$19.10▼$19.9350-Day Range$18.32▼$26.3452-Week Range$17.05▼$39.83Volume590,049 shsAverage Volume1.28 million shsMarket Capitalization$2.44 billionP/E RatioN/ADividend YieldN/APrice Target$42.70Consensus RatingModerate Buy Company OverviewArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Read More… Arrowhead Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScoreARWR MarketRank™: Arrowhead Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 134th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 7 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageArrowhead Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arrowhead Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($3.72) to ($3.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 12.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.09% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 6.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.55 Percentage of Shares Shorted8.09% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 6.56%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.44 News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Arrowhead Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest13 people have searched for ARWR on MarketBeat in the last 30 days. This is an increase of 550% compared to the previous 30 days.MarketBeat Follows26 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 2,500% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $895,553.00 in company stock.Percentage Held by InsidersOnly 4.50% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arrowhead Pharmaceuticals' insider trading history. Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Stock News HeadlinesInsider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $246,109.17 in StockDecember 24 at 4:37 AM | insidertrades.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 26,712 SharesDecember 21, 2024 | insidertrades.com[PDF] The Opportunity in GoldCommodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.December 25, 2024 | DTI (Ad)Arrowhead doses 1st patients in study of ARO-INHBE for obesity treatmentDecember 24 at 1:40 AM | markets.businessinsider.comArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of ObesityDecember 23 at 7:30 AM | businesswire.comArrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC WainwrightDecember 23 at 3:13 AM | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Rating Increased to Sell at StockNews.comDecember 23 at 2:11 AM | americanbankingnews.comIonis FDA approval a positive for Arrowhead, says H.C. WainwrightDecember 20, 2024 | markets.businessinsider.comSee More Headlines ARWR Stock Analysis - Frequently Asked Questions How have ARWR shares performed this year? Arrowhead Pharmaceuticals' stock was trading at $30.60 at the beginning of the year. Since then, ARWR stock has decreased by 35.8% and is now trading at $19.63. View the best growth stocks for 2024 here. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.80. The company's revenue was down 100.0% compared to the same quarter last year. Who are Arrowhead Pharmaceuticals' major shareholders? Top institutional shareholders of Arrowhead Pharmaceuticals include State Street Corp (5.11%), FMR LLC (4.88%), Geode Capital Management LLC (2.38%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.73%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, William D Waddill, Hongbo Lu, Victoria Vakiener and Adeoye Y Olukotun. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alliance Resource Partners (ARLP), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Netflix (NFLX). Company Calendar Last Earnings8/08/2024Today12/24/2024Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARWR CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees400Year FoundedN/APrice Target and Rating Average Stock Price Target$42.70 High Stock Price Target$80.00 Low Stock Price Target$24.00 Potential Upside/Downside+117.5%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($5.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-599,490,000.00 Net MarginsN/A Pretax Margin-17,247.54% Return on Equity-182.69% Return on Assets-64.04% Debt Debt-to-Equity Ratio2.06 Current Ratio6.74 Quick Ratio6.74 Sales & Book Value Annual Sales$3.55 million Price / Sales687.87 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book12.75Miscellaneous Outstanding Shares124,434,000Free Float118,834,000Market Cap$2.44 billion OptionableOptionable Beta0.91 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ARWR) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.